Newsletter sign up


ADC University Our services

ADC Review
is made possible by:



Copyright 2017
Terms & Conditions


Author Instructions

ADC Review: Journal of Antibody-drug Conjugates does not consider pre-submission inquiries. All submissions should be prepared with the following files:

  • Cover letter
  • Manuscript, including tables and figure legends
  • Figures/Tables

Cover Letter
Your cover letter should be approximately one page including:

  • Concisely summarizes why your paper is a valuable addition to the scientific literature
  • Briefly relates your study to previously published work
  • Specifies the type of article you are submitting (for example, research article, systematic review, meta-analysis, clinical trial)
  • Describes any prior interactions with ADC Review: Journal of Antibody-drug Conjugates and/or InPress Media Group, LLC regarding the submitted manuscript
  • Suggests appropriate academic/scientific editors to review your manuscript
  • Lists any recommended or opposed reviewers

ADC Review: Journal of Antibody-drug Conjugates is an Open Access Journal. Therefore, your cover letter should not include requests to reduce or waive open access publication fees. If your manuscript be accepted, you will have the opportunity to include your requests at that time.

Manuscript Organization
ADC Review: Journal of Antibody-drug Conjugates considers manuscripts of any length. There are no explicit restrictions for the number of words, figures, or the length of the supporting information, although we encourage a concise and accessible writing style. We will not consider monographs. Also:

  • All manuscripts should include line numbers and page numbers.
  • Manuscripts should begin with the ordered sections:
    • Title
    • Authors
    • Affiliations
    • Abstract
    • Introduction

and end with the sections of:

  • Acknowledgments
  • References
  • Figure Legends
  • Tables

Figures and Tables
Figures should never be included in the main manuscript file. Each figure must be prepared and submitted in separate and individual files.

Manuscript data and organization
The title, authors, and affiliations should all be included on a title page as the first page of the manuscript file.

There are no explicit requirements for section organization between these beginning and ending sections. Manuscripts may be organized in different ways and with different section titles, according to the authors’ preference. However, in most cases, internal sections include:

  • Materials and Methods
  • Results
  • Discussion
  • Conclusions (optional)

ADC Review: Journal of Antibody-drug Conjugates has no specific requirements for the order of these sections, and in some cases it may be appropriate to combine a number of sections.

Abbreviations
Abbreviations should be kept to a minimum and defined upon first use in the text. Non-standard abbreviations should not be used unless they appear at least three times in the manuscript.

Standardized nomenclature should be used as appropriate, including appropriate usage of species names and SI units.

File Type Requirements
Authors should submit their manuscript files in Word (as .doc or .docx) or RTF format. PDF-files are acceptable during the review process, however, only RTF and .doc /.docx files can be used during production.

General Guidelines

Title
Manuscripts must be submitted with both a full title and a short title. The full title should be included in the manuscript file; the short title will be entered during the online submission process.

Full manuscript title
The full title should be 150 characters or less. The title should be specific, descriptive, concise, and comprehensible to readers outside the subject field. Do not use abbreviations in the title.

Concise titles are easier to read than long, convoluted ones. Titles that are too short may, however, lack important information, such as study design (which is particularly important in identifying randomized, controlled trials). Authors should include all information in the title that will make electronic retrieval of the manuscript both sensitive and specific.

Short Title
The short title should be 50 characters or less and should state the topic of the paper.

Authors and Affiliations
All author names should be listed in the following order:

  • First names (or initials, if used),
  • Middle names (or initials, if used),
  • Last names (surname, family name)
  • Highest academic degree(s)

Each author should list an associated department, university, organizational or corporate affiliation and its location, including city, state/province (if applicable), and country. If the article has been submitted on behalf of a consortium, all author names and affiliations should be listed at the end of the article.

ADC Review: Journal of Antibody-drug Conjugates does not allow any changes in this information after initial submission.

To qualify for authorship, authors should contribute to all of the following:

  • Conception and design of the work, acquisition of data, or analysis and interpretation of data
  • Drafting the article or revising it critically for important intellectual content
  • Final approval of the version to be published

Individuals designated as authors should qualify for authorship, and all those who qualify should be listed. Each author must have participated sufficiently in the work to take public responsibility for appropriate portions of the content. Individuals who have contributed to the work but do not qualify for authorship should be listed in the acknowledgments and not be included in the list of authors.

When a large organization, a group or center has conducted the work, the author list should include the individuals whose contributions meet the criteria defined above, as well as the group name(s).

Other items to be included:

  • The name of the department(s) and institution(s) to which the work should be attributed.
  • Disclaimers, if any.
  • The name and address of the author to whom requests for reprints should be addressed or a statement that reprints are not available from the author(s).
  • Source(s) of support in the form of grants, equipment, drugs, or all of these.

Corresponding author
Contact information for corresponding authors. The name, mailing address, telephone and fax numbers, and e-mail address of the author responsible for correspondence about the manuscript (the “corresponding author;” this author may or may not be the “guarantor” for the integrity of the study). The corresponding author should indicate clearly whether his or her e-mail address can be published. In general, this information will be published with the article if accepted.

Abstract
Structured abstracts are preferred for original research and systematic reviews. The abstract should provide the context or background for the study and should state the study’s purpose, basic procedures (selection of study subjects or laboratory animals, observational and analytical methods), main findings (giving specific effect sizes and their statistical significance, if possible), principal conclusions, and funding sources. It should emphasize new and important aspects of the study or observations. Articles on clinical trials should contain abstracts that include the items that the CONSORT group has identified as essential.

The manuscript’s abstract should:

  • Describe the main objective(s) of the study/review
  • Explain how the study/review was executed
  • Summarize the most important results/conclusions and their significance
  • Not exceed 500 words

Abstracts should not include:

  • Citations
  • Abbreviations, if possible

Introduction
The introduction should:

  • Provide a clear background that puts the manuscript into context and allows readers outside the field to understand the purpose and significance of the study/review
  • Define the problem addressed and why it is important
  • Include a brief review of the key literature
  • Note any relevant controversies or disagreements in the field
  • Conclude with a brief statement of the overall aim of the work and a comment about whether that aim has been achieved

Materials and Methods
The Methods section should include only information that was available at the time the plan or protocol for the study was being written; all information obtained during the study belongs in the Results section

Technical information
Where applicable, identify the methods, apparatus (give the manufacturer’s name and address in parentheses), and procedures in sufficient detail to allow others to reproduce the results. Give references to established methods, including statistical methods (see below); provide references and brief descriptions for methods that have been published but are not well-known; describe new or substantially modified methods, give the reasons for using them, and evaluate their limitations. Identify precisely all drugs and chemicals used, including generic name(s), dose(s), and route(s) of administration.

Authors submitting review manuscripts should include a section describing the methods used for locating, selecting, extracting, and synthesizing data. These methods should also be summarized in the abstract.

Statistics
The author(s) should describe statistical methods with enough detail to enable a knowledgeable reader with access to the original data to verify the reported results. When possible, quantify findings and present them with appropriate indicators of measurement error or uncertainty (such as confidence intervals). Avoid relying solely on statistical hypothesis testing, such as P values, which fail to convey important information about effect size. References for the design of the study and statistical methods should be to standard works when possible (with pages stated). Define statistical terms, abbreviations, and most symbols. Specify the kind (including version) of computer software used.

Results, Discussion, and Conclusions
The Results, Discussion and Conclusion sections of the submitted manuscript may either be all be separate or be combined to create a mixed section. These sections may be divided into subsections, each with a concise subheading, as appropriate. While these sections have no word limit, the language should be clear and concise.

Together, these sections should describe the results of the study trials/experiments, the interpretation of these results, and the conclusions that can be drawn from them. Author(s) should explain how these results relate to the hypothesis presented as the basis of the study/review and provide a succinct explanation of the implications of the findings, particularly in relation to previous related studies and potential future directions for research.

Acknowledgments
People who contributed to the work but do not fit the publication’s criteria should be listed in the acknowledgments. This section should also list their specific contributions to the submitted manuscript. Please ensure that any individual(s) named in the acknowledgments agrees to being named.

Funding
Funding sources should not be included in the acknowledgments, or anywhere in the manuscript To prevent potential conflicts of interest from being overlooked or misplaced, this information needs to be part of the initial submission documentation. This information needs to be provided in the competing interests/conflicts of interest disclosure section (and listed on the disclosure form developed by the International Committee of Medical Journal Editors )

References
Only previously published or accepted manuscripts should be included in the reference list. Manuscripts that have been submitted but not yet accepted should not be cited or included. Limited citation of unpublished work should be included in the body of the text only as “unpublished data.”

References must be listed at the end of the manuscript and numbered in the order that they appear in the manuscript. In the text, citations should be indicated by the reference number in brackets. Journal name abbreviations should be the same as those found in the NCBI databases. To make referencing easier, use reference software including (Reference ManagerEndNote).

Tables
Tables capture information concisely and display it efficiently; they also provide information at any desired level of detail and precision. Including data in tables rather than text frequently makes it possible to reduce the length of the text.

Tables should be included at the end of the submitted manuscript. All tables should have a clear and concise title. Footnotes can be used to explain abbreviations. Citations should be indicated using the same style. Tables occupying more than one printed page should be avoided, if possible

Type or print each table with double-spacing on a separate sheet of paper (or file). Number tables consecutively in the order of their first citation in the text and supply a brief title for each. Do not use internal horizontal or vertical lines. Give each column a short or an abbreviated heading. Authors should place explanatory matter in footnotes, not in the heading. Explain all nonstandard abbreviations in footnotes, and use the following symbols, in sequence:

*, †, ‡, §, ||, ¶, **, ††, ‡‡, §§, ||||, ¶¶, etc.

Also:

  • Identify statistical measures of variations, such as standard deviation and standard error of the mean.
  • Be sure that each table is cited in the text.
  • If you use data from another published or unpublished source, obtain permission and acknowledge that source fully.

Illustrations / Figure Legends
Figures should not be included in the manuscript file but be submitted as separate files during submission. However, figure /illustration legends should be included in the manuscript.

Figures should be either professionally drawn and photographed, or submitted as photographic-quality digital prints. In addition to requiring a version of the figures suitable for printing, we ask authors for electronic files of figures in a specific format (JPEG or GIF) that will produce high-quality online images; authors should review the images on a computer screen before submitting them to be sure they meet their own quality standards.

For x-ray films, scans, and other diagnostic images, as well as pictures of pathology specimens or photomicrographs, send sharp, glossy, black-and-white or color photographic prints, usually 127 x 173 mm (5 x 7 inches). Letters, numbers, and symbols on figures should be clear and consistent throughout, and large enough to remain legible when the figure is reduced for publication. Figures should be made as self-explanatory as possible, since many will be used directly in slide presentations. Note that titles and detailed explanations belong in the legends – not on the illustrations themselves.

Also:

  • Photomicrographs should have internal scale markers. Symbols, arrows, or letters used in photomicrographs should contrast with the background.
  • Photographs of potentially identifiable people must be accompanied by written permission to use the photograph.
  • Figures should be numbered consecutively according to the order in which they have been cited in the text. If a figure has been published previously, acknowledge the original source and submit written permission from the copyright holder to reproduce the figure. Permission is required irrespective of authorship or publisher except for documents in the public domain.
  • Before submitting any illustration or figure, please consult our creative team.

Figure legends
Figure legends should describe the key messages of a figure. Legends should have a short title of 15 words or less. The full legend should have a description of the figure and allow readers to understand the figure without referring to the text. The legend itself should be clear and succinct, avoid lengthy descriptions of methods, and define all non-standard symbols and abbreviations.

Units of Measurement
Measurements of length, height, weight, and volume should be reported in metric units (meter, kilogram, or liter) or their decimal multiples.

Also:

  • Temperatures should be in degrees Celsius. Blood pressures should be in millimeters of mercury.
  • Authors should report laboratory information in both local and International System of Units (SI). Drug concentrations may be reported in either SI or mass units, but the alternative should be provided in parentheses where appropriate.

Abbreviations and Symbols
ADC Review: Journal of Antibody-drug Conjugates asks authors to use only standard abbreviations. The use of nonstandard abbreviations can be confusing to readers. Please avoid abbreviations in the title of the manuscript. The spelled-out abbreviation followed by the abbreviation in parenthesis should be used on first mention unless the abbreviation is a standard unit of measurement.

General requirements
Other items to be included in the submission file:

  • A running head.ADC Review: Journal of Antibody-drug Conjugates request a short running head or footline, usually no more than 40 characters (including letters and spaces) at the foot of the title page. The “Running head” will be published in the journals and are used by the editors for filing and locating manuscripts.
  • Word counts.A word count for the text only (excluding abstract, acknowledgments, figure legends, and references). This allows editors and reviewers to assess whether the information contained in the paper warrants the amount of space devoted to it, and whether the submitted manuscript fits within the journal’s word limits. A separate word count for the Abstract is useful for the same reason.
  • The number of figures and tables.It is difficult for editorial staff and reviewers to determine whether the figures and tables that should have accompanied a manuscript were actually included unless the numbers of figures and tables are noted on the title page.

Specific Reporting Guidelines

Experiments on Human Subject
When reporting experiments on human subjects, authors should indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study. When reporting experiments on animals, authors should indicate whether the institutional and national guide for the care and use of laboratory animals was followed.

Clinical Trials
Authors of manuscripts describing the results of clinical trials must adhere to the CONSORT reporting guidelines appropriate to their trial design, available on the CONSORT Statement website. Before the paper can enter peer review, authors must:

  • Provide the registry name and number in the methods section of the manuscript
  • Provide a copy of the trial protocol as approved by the ethics committee and a completed CONSORT checklist as Supporting Information (which will be published alongside the paper, if accepted)
  • Include the CONSORT flow diagram as the manuscript’s “Figure 1”

Any deviation from the trial protocol must be explained in the paper. Authors must explicitly discuss informed consent in their paper, and we reserve the right to ask for a copy of the patient consent form.

The methods section must include the name of the registry, the registry number, and the URL of your trial in the registry database for each location in which the trial is registered.

Animal Research
Methods sections of manuscripts reporting results of animal research must include required ethics statements that specify:

  • The full name of the relevant ethics committee that approved the work, and the associated permit number(s) (where ethical approval is not required, the manuscript should include a clear statement of this and the reason why this is not required)
  • Relevant details for efforts taken to ameliorate animal suffering

The organism(s) studied should always be stated in the abstract. Where research may be confused as pertaining to clinical research, the animal model should also be stated in the title.

We encourage authors to use the ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines as a reference.

Cell Line Research
Methods sections for submissions reporting on research with cell lines should state the origin of any cell lines. For established cell lines the provenance should be stated and references must also be given to either a published paper or to a commercial/corporate source. If previously unpublished de novo cell lines were used, including those gifted from another laboratory, details of institutional review board or ethics committee approval must be given, and confirmation of written informed consent must be provided if the line is of human origin.

Systematic Review/Meta-Analysis
A systematic review paper, as defined by The Cochrane Collaboration, is a review of a clearly formulated question that uses explicit, systematic methods to identify, select, and critically appraise relevant research, and to collect and analyze data from the studies that are included in the review. These reviews differ substantially from narrative-based reviews or synthesis articles. Statistical methods (meta-analysis) may or may not be used to analyze and summarize the results of the included studies.

Reports of systematic reviews and meta-analyses must include a completed PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) checklist and flow diagram to accompany the main text. Blank templates are available here:

ADC Review: Journal of Antibody-drug Conjugates requires authors to also state in their “Methods” section whether a protocol exists for their systematic review, and if so, provide a copy of the protocol as Supporting Information and provide the registry number in the abstract.

If your article is a Systematic Review or a Meta-Analysis you should:

  • State this in your cover letter
  • Select “Research Article” as your article type when submitting
  • Include the PRISMA flowchart as Figure 1 (required where applicable)
  • Include the PRISMA checklist as Supporting Information

Obligation to register Clinical Trials
The publishers and editors of ADC Review: Journal of Antibody-drug Conjugates believes that it is important to foster a comprehensive, publicly available database of clinical trials. We define a clinical trial as any research project that prospectively assigns human subjects to intervention or concurrent comparison or control groups to study the cause-and-effect relationship between a medical intervention and a health outcome. Medical interventions include drugs, surgical procedures, devices, behavioral treatments, process-of-care changes, and the like.

ADC Review: Journal of Antibody-drug Conjugates requires, as a condition of consideration for publication, registration in a public trials registry.

While we do not advocate one particular registry, we require authors to register their trial in a registry that meets several criteria:

  • The registry must be accessible to the public at no charge.
  • It must be open to all prospective registrants and managed by a not-for-profit organization.
  • There must be a mechanism to ensure the validity of the registration data,
  • The registry should be electronically searchable.
  • Trial registration with missing fields or fields that contain uninformative terminology is inadequate, does not meet the journal’s standard and, as a result may lead to the rejection of submitted manuscript

Language standards
Prior to submission, we encourage foreign language (non English) author(s) who believe their manuscripts will benefit from professional editing to use language-editing and copyediting services. It will be the responsibility of the authors to obtain this service. Please note that submissions are not copyedited before publication. A manuscript that does not meet the journal’s language standards, it may be rejected.


Page last updated April 18, 2013


Manuscript Guidelines & Tips Lonza

Featured Event

Topics to be Covered Introduction To Antibody Conjugates Overview Of Techniques In Quantitative Pharmacology No Such Thing As A Magic Bullet: The Hidden Challenges Of ADC Discovery And Development...


Skip to toolbar